Clinical outcomes of dolutegravir treatment in people living with HIV in Brazil: protocol for the CODE cohort

The Clinical Outcomes of Dolutegravir Treatment in People Living with HIV in Brazil (CODE) cohort study is a multicenter, prospective, observational study designed to evaluate the safety and efficacy of Dolutegravir (DTG)-based antiretroviral therapy (ART) among people living with HIV across diverse settings in Brazil. With the recent global shift towards DTG as a preferred option for first-line ART, particularly in low- and middle-income countries, there is vital need for comprehensive real-world data to inform its widespread use. CODE aims to fill this knowledge gap by assessing the clinical outcomes of both ART-naïve and ART-experienced patients initiating DTG-based regimens, as well as those who have switched from non-DTG-based ART. The primary objective of this study is to determine the proportion of patients who discontinue DTG due to any adverse events, specifically focusing on metabolic and psychiatric outcomes. Secondary objectives include evaluating the rates of virological suppression, the occurrence of immune reconstitution inflammatory syndrome (IRIS), changes in body mass index (BMI), and the development of HIV drug resistance. The CODE cohort will enroll approximately 5000 participants from multiple clinical sites across Brazil, including 2500 ART-naïve individuals, 1000 patients switching to DTG-based regimens for various reasons, and a comparator group of 1500 individuals who initiated non-DTG-based ART between 2013 and 2016, before DTG was available in the country. Participants will be followed for up to 36 months, with data collection points at baseline, 6, 12, 24, and 36 months. This study is expected to generate critical insights into the long-term outcomes associated with DTG-based ART, particularly in real-world settings that reflect the complexities of routine clinical care. By providing robust data on the effectiveness and safety of DTG in a diverse patient population, the CODE study aims to contribute to the optimization of HIV treatment strategies both in Brazil and globally.Key words: HIV-1, Dolutegravir, Outcomes, Brazil.

Authors

Institutions

Publication Details

Journal
BMC Infectious Diseases
Published
2025-10-08
DOI
https://doi.org/10.1186/s12879-025-11700-0
Primary Topic
HIV/AIDS drug development and treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical outcomes of dolutegravir treatment in people living with HIV in Brazil: protocol for the CODE cohort

Marcus Lacerda, Alexandre Naime Barbosa, Cristina Murray‐Krezan, Eduardo Sprinz et al.
BMC Infectious Diseases
HIV/AIDS drug development and treatment
article

Clinical outcomes of dolutegravir treatment in people living with HIV in Brazil: protocol for the CODE cohort

Marcus Lacerda, Alexandre Naime Barbosa, Cristina Murray‐Krezan, Eduardo Sprinz, Fernando Dutra, Tâmara Newman, Estela Luz, Jess Anderson, Marco Patelli, Cristiani Stelitano, Roberto Zajdenverg, Mary D. Carmody, Aline de Oliveira Ramalho, Mônica Baumgardt Bay, Valdez Madruga, Carlos Brites, Karen Mirna Loro Morejón, Kimberly Ann Page, Tânia Reuter, Sandra Wagner Cardoso, Benjamin Chase, Fábio Tiraboschi Leal, Bryn Jones, Alejandro Aragon, Fabianna Bahia, Rosa Dea Sperhack
article en

Abstract

The Clinical Outcomes of Dolutegravir Treatment in People Living with HIV in Brazil (CODE) cohort study is a multicenter, prospective, observational study designed to evaluate the safety and efficacy of Dolutegravir (DTG)-based antiretroviral therapy (ART) among people living with HIV across diverse settings in Brazil. With the recent global shift towards DTG as a preferred option for first-line ART, particularly in low- and middle-income countries, there is vital need for comprehensive real-world data to inform its widespread use. CODE aims to fill this knowledge gap by assessing the clinical outcomes of both ART-naïve and ART-experienced patients initiating DTG-based regimens, as well as those who have switched from non-DTG-based ART. The primary objective of this study is to determine the proportion of patients who discontinue DTG due to any adverse events, specifically focusing on metabolic and psychiatric outcomes. Secondary objectives include evaluating the rates of virological suppression, the occurrence of immune reconstitution inflammatory syndrome (IRIS), changes in body mass index (BMI), and the development of HIV drug resistance. The CODE cohort will enroll approximately 5000 participants from multiple clinical sites across Brazil, including 2500 ART-naïve individuals, 1000 patients switching to DTG-based regimens for various reasons, and a comparator group of 1500 individuals who initiated non-DTG-based ART between 2013 and 2016, before DTG was available in the country. Participants will be followed for up to 36 months, with data collection points at baseline, 6, 12, 24, and 36 months. This study is expected to generate critical insights into the long-term outcomes associated with DTG-based ART, particularly in real-world settings that reflect the complexities of routine clinical care. By providing robust data on the effectiveness and safety of DTG in a diverse patient population, the CODE study aims to contribute to the optimization of HIV treatment strategies both in Brazil and globally.Key words: HIV-1, Dolutegravir, Outcomes, Brazil.

BMC Infectious DiseasesVol. 25(1)
University of North Carolina at Chapel Hill (US), Universidade Federal da Bahia (BR), Universidade Municipal de São Caetano do Sul (BR), University of New Mexico (US), University of Pittsburgh (US), Universidade de Caxias do Sul (BR), Universidade Federal do Rio Grande do Norte (BR), Fundação de Medicina Tropical (BR), Instituto de Infectologia Emílio Ribas (BR), Hospital de Clínicas de Porto Alegre (BR), Universidade Iguaçu (BR), ViiV Healthcare (United Kingdom) (GB), Fundação Bahiana de Infectologia (BR), Centro de Referência em Informação Ambiental (BR), Centro Universitário do Espírito Santo (BR), Centro de Estudos Educação e Sociedade (BR), Instituto Evandro Chagas (BR), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (BR), Fundação Estadual de Produção e Pesquisa em Saúde (BR), GlaxoSmithKline (Brazil) (BR), Universidade Estadual Paulista (Unesp) (BR)
ViiV Healthcare
Openalex Percentile: Top 67%
HIV/AIDS drug development and treatment
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.